DE4CC0DE-5FC3-4494-BCBF-4D50B00366B5

GlaxoSmithKline Chairman Hampton To Step Down

By Steve Wynne-Jones
Share this article
GlaxoSmithKline Chairman Hampton To Step Down

GlaxoSmithKline Plc Chairman Philip Hampton will step down after more than three and a half years in the role, Britain's biggest drugmaker announced on Monday.

The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products.

Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction.

Right Moment

"Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

Before joining GSK, Hampton was chairman of Royal Bank of Scotland Group Plc and J Sainsbury plc.

ADVERTISEMENT

GSK, which is looking to buy early-stage assets and partner with companies, said it had started the search for a successor.

News by Reuters, edited by ESM. Click subscribe to sign up to ESM: European Supermarket Magazine.

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.